Serum Levels of HER2 ECD Can Determine the Response Rate to Low Dose Oral Cyclophosphamide and Methotrexate in Patients with Advanced Stage Breast Carcinoma

Research output: Contribution to journalArticle

Abstract

Background: The proto-oncogene HER2/neu encodes for a transmembrane receptor protein whose overexpression in breast cancer may be associated with poor prognosis. Its extracellular domain (HER2 ECD) can be shed into the circulation. The purpose of this study was to evaluate the predictive value of HER2 ECD in patients with advanced breast cancer. Patients and Methods: HER2 ECD was determined in 39 patients with advanced breast cancer, treated with oral cyclophosphamide and methotrexate (CM) at low doses. HER2 ECD levels were determined with the Bayer Immuno 1 HER2/neu assay before and after 2 months of chemotherapy, when all the patients were re-evaluated. Results: Based on the response to chemotherapy, the patients were divided into two groups: progressive disease (PD, 14 patients) and patients with clinical benefit (CB; Le. patients with stable or responsive disease, 25 patients). The patients with PD had a mean baseline value of HER2 ECD of 38.3±69.2 ng/ml while the group of CB showed lower levels (9.2±2.3 ng/ml p

Original languageEnglish
Pages (from-to)1261-1266
Number of pages6
JournalAnticancer Research
Volume24
Issue number2 C
Publication statusPublished - Mar 2004

Keywords

  • Breast cancer
  • Chemotherapy
  • HER2
  • Predictive value
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Serum Levels of HER2 ECD Can Determine the Response Rate to Low Dose Oral Cyclophosphamide and Methotrexate in Patients with Advanced Stage Breast Carcinoma'. Together they form a unique fingerprint.

  • Cite this